Peripheral Metabolic Effects of Somatostatin

University of Aarhus8 enrolled

Overview

The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Acromegaly Growth Hormone Deficiency Diabetes

Interventions

SomatostatinDRUG

4 h of 150 microgram infusion

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI \< 27 kg/m2 * Written informed consent * Healthy Exclusion Criteria: * Any disease * Any use of medications * Present or previous malignancy * Alcohol dependency * Allergy to trial medication

Locations (1)

Medical department M

Aarhus, Aarhus, Denmark

Outcomes

Primary Outcomes

Plasma levels of glucose

Time frame: 3 months

Secondary Outcomes

GH signalling

Time frame: one year

Serum levels of free fatty acids (FFA)

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.